Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264

Pan-cancer single-cell landscape of tumor-infiltrating T cells

Zheng, L., Qin, S., Si, W., Wang, A., Xing, B., Gao, R., Ren, X., Wang, L., Wu, X., Zhang, J., et al. (2021) · Science · doi:10.1126/science.abe6474 · Cited by 1,402

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360

CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability

Ma, X., Xiao, L., Liu, L., Ye, L., Pan, S., Bi, E., Wang, Q., Yang, M., Qian, J., & Yi, Q. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.02.015 · Cited by 1,048

ImmuCellAI: A Unique Method for Comprehensive T‐Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy

Miao, Y., Zhang, Q., Lei, Q., Luo, M., Xie, G., Wang, H., & Guo, A. (2020) · Advanced Science · doi:10.1002/advs.201902880 · Cited by 967

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis

Turajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Bakir, M. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 967

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance

Wu, W. E., Klockow, J., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 877

TIP: A Web Server for Resolving Tumor Immunophenotype Profiling

Xu, L., Deng, C., Pang, B., Zhang, X., Liu, W., Liao, G., Yuan, H., Peng, C., Li, F., Long, Z., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0689 · Cited by 700

Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers

Teo, M. Y., Seier, K., Ostrovnaya, I., Regazzi, A. M., Kania, B. E., Moran, M. M., Cipolla, C. K., Bluth, M. J., Chaim, J., Al-Ahmadie, H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.7740 · Cited by 544

Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β

Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 502

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis

Wang, P., Chen, Y., Song, S., Wang, T., Ji, W., Li, S., Liu, N., & Yan, C. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00730 · Cited by 479

Androgen receptor activity in T cells limits checkpoint blockade efficacy

Guan, X., Polesso, F., Wang, C., Sehrawat, A., Hawkins, R. M., Murray, S., THOMAS, G. V., Caruso, B., Thompson, R. F., Wood, M. A., et al. (2022) · Nature · doi:10.1038/s41586-022-04522-6 · Cited by 408

Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response

Hu, F., Liu, C., Liu, L., Zhang, Q., & Guo, A. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa176 · Cited by 355

Overcoming resistance to tumor-targeted and immune-targeted therapies

Aldea, M., Andre, F., Marabelle, A., Dogan, S., Barlesi, F., & Soria, J.-C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1638 · Cited by 311

Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma

Connor, A. A., Denroche, R. E., Jang, G. H., Timms, L. E., Kalimuthu, S. N., Selander, I., McPherson, T. A., Wilson, G. W., Chan‐Seng‐Yue, M., Borozan, I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3916 · Cited by 289

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

Karachaliou, N., Gonzalez-Cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-Capitan, A., Teixido, C., Molina-Vila, M. A., Viteri, S., De Los Llanos Gil, M., et al. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017749748 · Cited by 285

Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade

Jenkins, L., Jungwirth, U., Avgustinova, A., Iravani, M., Mills, A., Haider, S. A., Harper, J. A., & Isacke, C. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4141 · Cited by 293

Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

Gu, S. S., Zhang, W., Wang, X., Jiang, P., Traugh, N., Li, Z., Meyer, C., Stewig, B., Xie, Y., Bu, X., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0812 · Cited by 273

Sex-associated molecular differences for cancer immunotherapy

Ye, Y., Jing, Y., Liang, L., Mills, G. B., Diao, L., Liu, H., & Han, L. (2020) · Nature Communications · doi:10.1038/s41467-020-15679-x · Cited by 255

Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment

Zemek, R. M., de Jong, E., Chin, W. L., Schuster, I. S., Fear, V. S., Casey, T. H., Forbes, C., Dart, S., Leslie, C., Zaitouny, A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7816 · Cited by 213

The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Kim, K. H., Cho, J., Ku, B. M., Koh, J., Sun, J., Lee, S., Ahn, J. S., Cheon, J., Min, Y. J., Park, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1449 · Cited by 211

MuPeXI: prediction of neo-epitopes from tumor sequencing data

Bjerregaard, A.-M., Nielsen, M., Hadrup, S. R., Szállási, Z., & Eklund, A. C. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2001-3 · Cited by 200

A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma

Pozniak, J., Pedri, D., Landeloos, E., Van Herck, Y., Antoranz, A., Vanwynsberghe, L., Nowosad, A., Roda, N., Makhzami, S., Bervoets, G., et al. (2024) · Cell · doi:10.1016/j.cell.2023.11.037 · Cited by 199

LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy

Li, G., Kryczek, I., Nam, J., Li, X., Li, S., Li, J., Wei, S., Grove, S., Vatan, L., Zhou, J., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00672-3 · Cited by 194

Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy

Puig-Saus, C., Sennino, B., Peng, S., Wang, C. L., Pan, Z., Yuen, B., Purandare, B., An, D., Quach, B. B., Nguyen, D., et al. (2023) · Nature · doi:10.1038/s41586-023-05787-1 · Cited by 195

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation

Mehta, A., Kim, Y. J., Robert, L., Tsoi, J., Comı́n-Anduix, B., Berent-Maoz, B., Cochran, A. J., Economou, J. S., Tumeh, P. C., Puig-Saus, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1178 · Cited by 191

Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine

Conway, J. R., Kofman, E., Mo, S. S., Elmarakeby, H., & Van Allen, E. (2018) · Genome Medicine · doi:10.1186/s13073-018-0605-7 · Cited by 165

Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis

Gagliardi, M., Cotella, D., Santoro, C., Corà, D., Barlev, N. A., Piacentini, M., & Corazzari, M. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-2143-7 · Cited by 166

Synthetic lethality-mediated precision oncology via the tumor transcriptome

Lee, J. S., Nair, N. U., Dinstag, G., Chapman, L. M., Chung, Y., Wang, K., Sinha, S., Cha, H., Kim, D., Schperberg, A. V., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.030 · Cited by 158

The molecular feature of macrophages in tumor immune microenvironment of glioma patients

Zhang, H., Luo, Y., Wu, W., Zhang, L., Wang, Z., Dai, Z., Feng, S., Cao, H., Cheng, Q., & Liu, Z. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.019 · Cited by 150

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies

Jin, M., Fang, J., Peng, J., Wang, X., Xing, P., Jia, K., Hu, J., Wang, D., Ding, Y., Wang, X., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02176-8 · Cited by 162

Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma

Zhang, N., Zhang, H., Wu, W., Zhou, R., Li, S., Wang, Z., Dai, Z., Zhang, L., Liu, F., Liu, Z., et al. (2022) · Theranostics · doi:10.7150/thno.74281 · Cited by 142

Characterization of Glycolysis-Associated Molecules in the Tumor Microenvironment Revealed by Pan-Cancer Tissues and Lung Cancer Single Cell Data

Wei, J., Huang, K., Hu, M., Chen, Z., Bai, Y., Lin, S., & Du, H. (2020) · Cancers · doi:10.3390/cancers12071788 · Cited by 143

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers

Ock, C.-Y., Hwang, J., Keam, B., Kim, S.-B., Shim, J., Jang, H.-J., Park, S., Sohn, B. H., Cha, M., Ajani, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01018-0 · Cited by 136

Zika Virus Infects Human Sertoli Cells and Modulates the Integrity of the In Vitro Blood-Testis Barrier Model

Siemann, D. N., Strange, D. P., Maharaj, P. N., Shi, P., & Verma, S. (2017) · Journal of Virology · doi:10.1128/jvi.00623-17 · Cited by 135

Extracellular Vesicles in Cancer Drug Resistance: Roles, Mechanisms, and Implications

Yang, Q., Xu, J. B., Gu, J., Shi, H., Zhang, J., Zhang, J., Chen, Z., Fang, X., Zhu, T., & Zhang, X. (2022) · Advanced Science · doi:10.1002/advs.202201609 · Cited by 148

Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy

Mercogliano, M. F., Bruni, S., Mauro, F. L., Elizalde, P. V., & Schillaci, R. (2021) · Cancers · doi:10.3390/cancers13030564 · Cited by 145

Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers

Wu, H., Wang, Z., Zhao, Q., Chen, D., He, M.-M., Yang, L.-P., Wang, Y., Jin, Y., Ren, C., Luo, H., et al. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.10.116 · Cited by 132

Targeting immunosuppression by TGF-β1 for cancer immunotherapy

de Streel, G., & Lucas, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114697 · Cited by 131

Acquired resistance in cancer: towards targeted therapeutic strategies

Soragni, A., Knudsen, E. S., O’Connor, T. N., Tognon, C. E., Tyner, J. W., Gini, B., Kim, D., Bivona, T. G., Zang, X., Witkiewicz, A. K., et al. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00824-9 · Cited by 151

Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response

Mardis, E. R. (2019) · Genome Medicine · doi:10.1186/s13073-019-0684-0 · Cited by 124

Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment

Saab, S., Zalzale, H., Rahal, Z., Khalifeh, Y., Sinjab, A. F., & Kadara, H. N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00159 · Cited by 122

A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer

Chen, H., & Liang, H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.020 · Cited by 125

Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?

Ziogas, D. C., Theocharopoulos, C., Koutouratsas, T., Haanen, J. B. A. G., & Gogas, H. J. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102499 · Cited by 122

Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma

Xiong, Z., Chan, S. L., Zhou, J., Vong, J. S. L., Kwong, T. T., Zeng, X., Wu, H., Cao, J., Tu, Y., Feng, Y., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-328364 · Cited by 122

Vitamin D–VDR Signaling Inhibits Wnt/β-Catenin–Mediated Melanoma Progression and Promotes Antitumor Immunity

Muralidhar, S., Filia, A., Nsengimana, J., Poźniak, J., O'Shea, S. J., Diaz, J. M. S., Harland, M., Randerson‐Moor, J. A., Reichrath, J., Laye, J. P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3927 · Cited by 115

Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma

Lepletier, A., Madore, J., O’Donnell, J. S., Johnston, R. L., Li, X.-Y., McDonald, E., Ahern, E. S., Kuchel, A., Eastgate, M. A., Pearson, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3925 · Cited by 110

Mechanisms of Drug Resistance in Melanoma

Winder, M. L., & Virós, A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_17 · Cited by 112

Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1

Lee, C., Bae, J.-H., Choe, E., Park, J., Park, S., Cho, H. J., Song, B., & Baek, M. (2022) · Theranostics · doi:10.7150/thno.68864 · Cited by 110

Multi-scale integrative analyses identify THBS2+ cancer-associated fibroblasts as a key orchestrator promoting aggressiveness in early-stage lung adenocarcinoma

Yang, H., Sun, B., Fan, L., Ma, W., Xu, K., Hall, S. R. R., Wang, Z., Schmid, R. A., Peng, R., Marti, T. M., et al. (2022) · Theranostics · doi:10.7150/thno.69590 · Cited by 107

Prognostic significance of immune landscape in tumour microenvironment of endometrial cancer

Li, B., & Wan, X. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15408 · Cited by 102

Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma

Yu, J., Yan, J., Guo, Q., Chi, Z., Tang, B., Zheng, B., Yu, J., Yin, T., Cheng, Z., Wu, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0475 · Cited by 100

Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer

Kobayashi, Y., Lim, S., & Yamaguchi, H. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.011 · Cited by 96

Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment

Onuma, A. E., Zhang, H., Huang, H., Williams, T. M., Noonan, A. M., & Tsung, A. (2020) · Gene Expression · doi:10.3727/105221620x15880179864121 · Cited by 95

PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy

Rolfes, V., Idel, C., Pries, R., Plötze‐Martin, K., Habermann, J. K., Gemoll, T., Bohnet, S., Latz, E., Ribbat‐Idel, J., Franklin, B. S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25446 · Cited by 97

Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival

Wood, M. A., Weeder, B. R., David, J. K., Nellore, A., & Thompson, R. F. (2020) · Genome Medicine · doi:10.1186/s13073-020-00729-2 · Cited by 94

Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors

Iivanainen, S., Ahvonen, J., Knuuttila, A., Tiainen, S., & Koivunen, J. P. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000531 · Cited by 92

Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC

Liu, J., Geng, R., Ni, S., Cai, L., Yang, S., Shao, F., & Bai, J. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.01.018 · Cited by 90

Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review

Tangella, L. P., Clark, M. E., & Gray, E. S. (2020) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2020.129736 · Cited by 92

Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis

Mo, J., Hu, X., Gu, L., Chen, B., Khadaroo, P. A., Shen, Z., Dong, L., Lv, Y., Chitumba, M. N., & Liu, J. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-1792-4 · Cited by 86

Combining PARP Inhibition, Radiation, and Immunotherapy: A Possible Strategy to Improve the Treatment of Cancer?

Césaire, M., Thariat, J., Candéias, S. M., Stefan, D., Saintigny, Y., & Chevalier, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123793 · Cited by 85

Machine learning-based tumor-infiltrating immune cell-associated lncRNAs for predicting prognosis and immunotherapy response in patients with glioblastoma

Zhang, H., Zhang, N., Wu, W., Zhou, R., Li, S., Wang, Z., Dai, Z., Zhang, L., Liu, Z., Zhang, J., et al. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac386 · Cited by 82

Identification of Distinct Immune Subtypes in Colorectal Cancer Based on the Stromal Compartment

Shen, R., Li, P., Li, B., Zhang, B., Feng, L., & Cheng, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01497 · Cited by 78

News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors

Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 76

Therapeutic strategies to remodel immunologically cold tumors

Wang, M., Wang, S., Desai, J., Trapani, J. A., & Neeson, P. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1226 · Cited by 79

Single-cell N6-methyladenosine regulator patterns guide intercellular communication of tumor microenvironment that contribute to colorectal cancer progression and immunotherapy

Gao, Y., Wang, H., Chen, S., An, R., Chu, Y., Li, G., Wang, Y., Xie, X., & Zhang, J. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03395-7 · Cited by 71

An artificial intelligence network‐guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms

Zhang, N., Zhang, H., Liu, Z., Dai, Z., Wu, W., Zhou, R., Li, S., Wang, Z., Liang, X., Wen, J., et al. (2023) · Cell Proliferation · doi:10.1111/cpr.13409 · Cited by 71

Evolution of MHC-based technologies used for detection of antigen-responsive T cells

Bentzen, A. K., & Hadrup, S. R. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1971-5 · Cited by 71

The Landscape of Tumor Fusion Neoantigens: A Pan-Cancer Analysis

Wei, Z., Zhou, C., Zhang, Z., Guan, M., Zhang, C., Liu, Z., & Liu, Q. (2019) · iScience · doi:10.1016/j.isci.2019.10.028 · Cited by 67

Histone modifications in drug-resistant cancers: From a cancer stem cell and immune evasion perspective

Jin, M. L., & Jeong, K. W. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01014-z · Cited by 69

Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer

Zhuang, H., Zhou, Z., Ma, Z., Li, Z., Liu, C., Huang, S., Zhang, C., & Hou, B. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15990 · Cited by 60

NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer

Cui, Y., Li, Q., Li, W., Wang, Y., Lv, F., Shi, X., Tang, Z., Shen, Z., Hou, Y., Zhang, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.574937 · Cited by 62

Pan‐cancer analyses reveal molecular and clinical characteristics of cuproptosis regulators

Wu, C., Tan, J., Wang, X., Qin, C., Long, W., Pan, Y., Li, Y., & Liu, Q. (2022) · iMeta · doi:10.1002/imt2.68 · Cited by 61

Emerging biomarkers for cancer immunotherapy in melanoma

Axelrod, M. L., Johnson, D. B., & Balko, J. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.004 · Cited by 58

DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in gastric cancer

Qi, M., Lu, Y., Ruan, D., Yu, K., Chen, Y., Xiao, M., Wang, Y., Liu, Z., Xu, R., Ju, H., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.03.023 · Cited by 57

The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma

Kim, S.-H., Roszik, J., Cho, S.-N., Ogata, D., Milton, D. R., Peng, W., Menter, D. G., Ekmekçioglu, S., & Grimm, E. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1163 · Cited by 56

EPHA5 mutation predicts the durable clinical benefit of immune checkpoint inhibitors in patients with lung adenocarcinoma

Huang, W., Lin, A., Luo, P., Liu, Y., Xu, W., Zhu, W., Wei, T., Lyu, Q., Guo, L., & Zhang, J. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0207-6 · Cited by 54

Transcriptional Spatial Profiling of Cancer Tissues in the Era of Immunotherapy: The Potential and Promise

Nerurkar, S. N., Goh, D. L. M., Cheung, C. C. L., Nga, P. Q. Y., Lim, J. C. T., & Yeong, J. P.-S. (2020) · Cancers · doi:10.3390/cancers12092572 · Cited by 57

Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance

Yang, M., Lin, C.-H., Wang, Y., Chen, K., Zhang, H., & Li, W. (2022) · Genome Medicine · doi:10.1186/s13073-022-01079-x · Cited by 54

The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance

Diazzi, S., Tartare‐Deckert, S., & Deckert, M. (2023) · Oncogenesis · doi:10.1038/s41389-023-00452-8 · Cited by 61

Navigating the immune landscape with plasma cells: A pan‐cancer signature for precision immunotherapy

Ye, B., Jiang, A., Feng, L., Wang, C., Liang, X., & Zhang, P. (2024) · BioFactors · doi:10.1002/biof.2142 · Cited by 54

Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment

Zhang, N., Zhang, H., Wang, Z., Dai, Z., Zhang, X., Cheng, Q., & Liu, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691811 · Cited by 49

Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma

Poźniak, J., Nsengimana, J., Laye, J. P., O'Shea, S. J., Diaz, J. M. S., Droop, A., Filia, A., Harland, M., Davies, J. R., Mell, T., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2864 · Cited by 51

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer

Zhang, W., Shi, F., Kong, Y., Li, Y., Sheng, C., Wang, S., & Wang, Q. (2021) · Cancer Medicine · doi:10.1002/cam4.4472 · Cited by 49

Development and Validation of a DNA Methylation-related Classifier of Circulating Tumour Cells to Predict Prognosis and to provide a therapeutic strategy in Lung Adenocarcinoma

Gu, X., Huang, X., Zhang, X., & Wang, C. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.75284 · Cited by 50

Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice

Zemek, R. M., Chin, W. L., Fear, V. S., Wylie, B., Casey, T. H., Forbes, C., Tilsed, C. M., Boon, L., Guo, B. B., Bosco, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32567-8 · Cited by 51

Succinate preserves CD8+ T cell fitness to augment antitumor immunity

Ma, K., Cheng, H., Wang, L., Xiao, H., Liu, F., Yang, Y. T., Xiao, Z., Tang, K., Li, S., Wang, G., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.07.017 · Cited by 57

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection

Banna, G. L., Passiglia, F., Colonese, F., Canova, S., Menis, J., Addeo, A., Russo, A. D., & Cortinovis, D. L. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.06.016 · Cited by 48

Heterogeneity induced GZMA-F2R communication inefficient impairs antitumor immunotherapy of PD-1 mAb through JAK2/STAT1 signal suppression in hepatocellular carcinoma

Gao, Y., Xu, Q., Li, X., Guo, Y. L., Zhang, B., Jin, Y., Zhu, C., Shen, Y., Yang, P., Shi, Y., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04654-7 · Cited by 47

Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes

Lu, T., Wang, S., Xu, L., Zhou, Q., Singla, N., Gao, J., Manna, S., Pop, L. M., Xie, Z., Chen, M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz3199 · Cited by 49

Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma

Lorenzo, S. D., Tovoli, F., & Trevisani, F. (2022) · Cancers · doi:10.3390/cancers14194616 · Cited by 53

Tumor-Secreted IFI35 Promotes Proliferation and Cytotoxic Activity of CD8+ T Cells Through PI3K/Akt/mTOR Signaling Pathway in Colorectal Cancer

Li, P., Zhou, D., Chen, D., Cheng, Y., Chen, Y., Lin, Z.-S., Zhang, X., Huang, Z., Cai, J., Huang, W., et al. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-023-00930-6 · Cited by 49

Pan-cancer evaluation of regulated cell death to predict overall survival and immune checkpoint inhibitor response

Zhang, W., Zhu, Y., Liu, H., Zhang, Y., Liu, H., Adegboro, A. A., Dang, R., Dai, L., Wanggou, S., & Li, X. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00570-5 · Cited by 49

Prognostic values and immune suppression of the S100A family in pancreatic cancer

Zhuang, H., Chen, X., Dong, F., Zhang, Z., Zhou, Z., Ma, Z., Huang, S., Chen, B., Zhang, C., & Hou, B. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16343 · Cited by 45

Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance

Voronova, V., Vislobokova, A., Mutig, K., Samsonov, M., Peskov, K. V., Sekacheva, M. I., Materenchuk, M. Y., Bunyatyan, N. D., & Lebedeva, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1035884 · Cited by 47

Novel immune checkpoint targets: A promising therapy for cancer treatments

Patwekar, M. F., Sehar, N., Patwekar, F., Medikeri, A., Ali, S., Aldossri, R. M., & Rehman, M. U. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111186 · Cited by 44

Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance

Popovic, A., & Tartare‐Deckert, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924553 · Cited by 46

Interleukin-16 enhances anti-tumor immune responses by establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice

Wen, Z., Liu, T., Xu, X., Acharya, N., Shen, Z., Lu, Y., Xu, J., Guo, K., Shen, S., Zhao, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57603-1 · Cited by 46

Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer

Wu, Z., Wang, M.-R., Liu, Q., Liu, Y., Zhu, K., Chen, L., Guo, H., Li, Y., & Shi, B. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.39056 · Cited by 43

The GENCODE exome: sequencing the complete human exome

Coffey, A. J., Kokocinski, F., Calafato, M., Scott, C., Palta, P., Drury, E., Joyce, C. J., LeProust, E. M., Harrow, J., Hunt, S. E., et al. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.28 · Cited by 64

The current landscape of clinical exome and genome reanalysis in the U.S.

Frees, M., Carter, J. N., Wheeler, M. T., & Reuter, C. M. (2024) · Journal of Genetic Counseling · doi:10.1002/jgc4.1968 · Cited by 5

Clinical Exome Performance for Reporting Secondary Genetic Findings

Park, J. Y., Clark, P., Londin, E. R., Sponziello, M., Kricka, L. J., & Fortina, P. M. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.231456 · Cited by 37

Exome Sequencing in Mendelian Disorders

Lee, J. (2010) · Journal of genetic medicine · doi:10.5734/jgm.2010.7.2.119 · Cited by 1

Diagnostic Exome Sequencing — Are We There Yet?

Mefford, H. C. (2012) · New England Journal of Medicine · doi:10.1056/nejme1211659 · Cited by 24